Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000641716 | Endometrium | AEH | regulation of translation | 94/2100 | 468/18723 | 1.14e-08 | 7.62e-07 | 94 |
GO:004572715 | Endometrium | AEH | positive regulation of translation | 38/2100 | 136/18723 | 6.37e-08 | 3.38e-06 | 38 |
GO:003425015 | Endometrium | AEH | positive regulation of cellular amide metabolic process | 42/2100 | 162/18723 | 1.35e-07 | 6.12e-06 | 42 |
GO:000915016 | Endometrium | AEH | purine ribonucleotide metabolic process | 68/2100 | 368/18723 | 2.26e-05 | 4.35e-04 | 68 |
GO:000913210 | Endometrium | AEH | nucleoside diphosphate metabolic process | 30/2100 | 124/18723 | 3.39e-05 | 6.05e-04 | 30 |
GO:004693910 | Endometrium | AEH | nucleotide phosphorylation | 26/2100 | 101/18723 | 3.57e-05 | 6.26e-04 | 26 |
GO:000913515 | Endometrium | AEH | purine nucleoside diphosphate metabolic process | 26/2100 | 103/18723 | 5.13e-05 | 8.25e-04 | 26 |
GO:000917915 | Endometrium | AEH | purine ribonucleoside diphosphate metabolic process | 26/2100 | 103/18723 | 5.13e-05 | 8.25e-04 | 26 |
GO:000616510 | Endometrium | AEH | nucleoside diphosphate phosphorylation | 25/2100 | 99/18723 | 7.05e-05 | 1.08e-03 | 25 |
GO:000616316 | Endometrium | AEH | purine nucleotide metabolic process | 70/2100 | 396/18723 | 7.46e-05 | 1.13e-03 | 70 |
GO:000918510 | Endometrium | AEH | ribonucleoside diphosphate metabolic process | 26/2100 | 106/18723 | 8.63e-05 | 1.27e-03 | 26 |
GO:000925910 | Endometrium | AEH | ribonucleotide metabolic process | 68/2100 | 385/18723 | 9.63e-05 | 1.39e-03 | 68 |
GO:19016539 | Endometrium | AEH | cellular response to peptide | 64/2100 | 359/18723 | 1.16e-04 | 1.63e-03 | 64 |
GO:001969310 | Endometrium | AEH | ribose phosphate metabolic process | 69/2100 | 396/18723 | 1.31e-04 | 1.79e-03 | 69 |
GO:000609610 | Endometrium | AEH | glycolytic process | 21/2100 | 81/18723 | 1.75e-04 | 2.26e-03 | 21 |
GO:007252116 | Endometrium | AEH | purine-containing compound metabolic process | 71/2100 | 416/18723 | 2.01e-04 | 2.54e-03 | 71 |
GO:000675710 | Endometrium | AEH | ATP generation from ADP | 21/2100 | 82/18723 | 2.10e-04 | 2.59e-03 | 21 |
GO:004343410 | Endometrium | AEH | response to peptide hormone | 70/2100 | 414/18723 | 2.93e-04 | 3.35e-03 | 70 |
GO:004603110 | Endometrium | AEH | ADP metabolic process | 22/2100 | 90/18723 | 3.09e-04 | 3.48e-03 | 22 |
GO:000911715 | Endometrium | AEH | nucleotide metabolic process | 78/2100 | 489/18723 | 8.39e-04 | 7.82e-03 | 78 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0001010 | Breast | Precancer | Glycolysis / Gluconeogenesis | 13/684 | 67/8465 | 2.39e-03 | 1.51e-02 | 1.16e-02 | 13 |
hsa052309 | Breast | Precancer | Central carbon metabolism in cancer | 13/684 | 70/8465 | 3.57e-03 | 2.17e-02 | 1.66e-02 | 13 |
hsa0120012 | Breast | Precancer | Carbon metabolism | 18/684 | 115/8465 | 4.79e-03 | 2.75e-02 | 2.11e-02 | 18 |
hsa052036 | Breast | Precancer | Viral carcinogenesis | 27/684 | 204/8465 | 7.19e-03 | 4.06e-02 | 3.11e-02 | 27 |
hsa0001013 | Breast | Precancer | Glycolysis / Gluconeogenesis | 13/684 | 67/8465 | 2.39e-03 | 1.51e-02 | 1.16e-02 | 13 |
hsa0523012 | Breast | Precancer | Central carbon metabolism in cancer | 13/684 | 70/8465 | 3.57e-03 | 2.17e-02 | 1.66e-02 | 13 |
hsa0120013 | Breast | Precancer | Carbon metabolism | 18/684 | 115/8465 | 4.79e-03 | 2.75e-02 | 2.11e-02 | 18 |
hsa0520312 | Breast | Precancer | Viral carcinogenesis | 27/684 | 204/8465 | 7.19e-03 | 4.06e-02 | 3.11e-02 | 27 |
hsa0520322 | Breast | IDC | Viral carcinogenesis | 34/867 | 204/8465 | 2.82e-03 | 1.86e-02 | 1.39e-02 | 34 |
hsa0520332 | Breast | IDC | Viral carcinogenesis | 34/867 | 204/8465 | 2.82e-03 | 1.86e-02 | 1.39e-02 | 34 |
hsa0520341 | Breast | DCIS | Viral carcinogenesis | 34/846 | 204/8465 | 1.88e-03 | 1.27e-02 | 9.33e-03 | 34 |
hsa052035 | Breast | DCIS | Viral carcinogenesis | 34/846 | 204/8465 | 1.88e-03 | 1.27e-02 | 9.33e-03 | 34 |
hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa0523010 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa0516512 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa0523013 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa01200 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
hsa00620 | Colorectum | AD | Pyruvate metabolism | 28/2092 | 47/8465 | 3.71e-07 | 5.41e-06 | 3.45e-06 | 28 |
hsa00010 | Colorectum | AD | Glycolysis / Gluconeogenesis | 34/2092 | 67/8465 | 3.63e-06 | 4.34e-05 | 2.77e-05 | 34 |
hsa05230 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5315 | PKM | ENZYME, KINASE, DRUGGABLE GENOME | | GNF-PF-2812 | CHEMBL125044 | |
5315 | PKM | ENZYME, KINASE, DRUGGABLE GENOME | | EBSELEN | EBSELEN | |
5315 | PKM | ENZYME, KINASE, DRUGGABLE GENOME | | SANGUINARIUM | SANGUINARIUM | |
5315 | PKM | ENZYME, KINASE, DRUGGABLE GENOME | | DNDI1417195 | CHEMBL1303948 | |
5315 | PKM | ENZYME, KINASE, DRUGGABLE GENOME | | CID 752709 | CHEMBL429335 | |
5315 | PKM | ENZYME, KINASE, DRUGGABLE GENOME | | CIS-RESVERATROL | CIS-RESVERATROL | |
5315 | PKM | ENZYME, KINASE, DRUGGABLE GENOME | | GNF-PF-1919 | CHEMBL576409 | |
5315 | PKM | ENZYME, KINASE, DRUGGABLE GENOME | | 1,4-BIS(4-METHOXYPHENYLSULFONYL)PIPERAZINE | CHEMBL1091502 | |
5315 | PKM | ENZYME, KINASE, DRUGGABLE GENOME | | TRANILAST | TRANILAST | |
5315 | PKM | ENZYME, KINASE, DRUGGABLE GENOME | | SULFADIAZINE, SILVER | SULFADIAZINE, SILVER | |